Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

View:
Post by fdfd12 on Dec 17, 2015 8:19am

CXR

forget about recognia, it says $18-$24.

In my opinion, there is GOOD and BAD with CXR.

THE GOOD

WIll do $6.50US which is $9CAN.
WIth a PE of 15, we get a TRUE price of $135CAN.
This is fair value TODAY.

THE BAD

WIth their 3.5B debt, they will only pay it off in 8 years (according to Andrew Mcreath).
Because of that, they will only have organic growth of 8% per year.
Sure they can buy small "tuck in acquisitions" as they have said, but a BIG MACHINE that CXR has been after buying AMCO, small tuck ins won't add much to the top or bottom line.

CONCLUSION:
CXR should be $135CAN and once there, will only move up about 10% until a good portion of the debt is paid off.
Then they can go after new MONSTERS.

any comments?
Comment by cg16 on Dec 17, 2015 8:30am
fdfd12, are you factoring in the 60 new drugs coming that aren't accounted for in the current guidance? did Mcreath factor those in? "tuck ins" + new drug sales + old drugs sold in new markets = good growth even while paying down debt. jmo
Comment by fdfd12 on Dec 17, 2015 8:52am
Why arenb't the 60 new ones accounted for?
Comment by cg16 on Dec 17, 2015 10:11am
("why aren't the 60 new ones accounted for")? are you suggesting that the sales performance and margin on the 60 drugs that aren't even launched yet are factored into the guidance? how would they predict that so early on? the other point about debt is that, as Mark "tucks in" acquistions, he will delever without paying any debt down. he will attack the debt in multiple ...more  
Comment by sunshine7 on Dec 17, 2015 9:18am
No company pays down debt to 0. If you can borrow money at 4% and ROI is 10% then that is good business sense. 2016 EPS is $9 (likely conservative) or total CD459M. With growth (8% organic plus opportunities), the debt is very manageable. Interest cost starts at CD338M and goes down as high cost bridge loans (9.5%) are paid first. Largest and longest loans are 4%ish. As debt ratio drops to less ...more  
Comment by Marcel7 on Dec 17, 2015 9:36am
Yes, a couple of comments. If your assumption is that they are paying down maximum debt each year and assuming the blended rate of around 7%, as they pay down debt they pay less interest. The savings on the interest would not be insignificant (if you are talking about roughly 300 million at over 9% or so for the highest cost debt). Since they will invariably pay down the highest cost debt first ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities